Back to Newsroom

Sigilon Therapeutics Appoints Eric Shaff to Board of Directors

CAMBRIDGE, Mass., Nov. 1, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the appointment of Eric Shaff, Chief Financial Officer of Seres Therapeutics (NASDAQ:MCRB), to the Sigilon Therapeutics board of directors. Mr. Shaff brings a long history of industry experience to the company’s board.